Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III supplemental study of batch consistency and scale bridging for a bivalent recombinant HPV vaccine
CTR20210788Phase 3Completed
- Sponsor
- Shanghai Zerun Biotechnology Co., Ltd.
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Walrinvax in human papillomavirus infection, sponsored by Shanghai Zerun Biotechnology Co., Ltd.. Started Apr 2021; status: completed.
02
Drugs
Walrinvax
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on CTR20210788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210788.